Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vorapaxar (MK-5348) 是抗血小板药物,是一种选择性、口服活性和竞争性的凝血酶受体蛋白酶激活受体(PAR-1)拮抗剂,Ki 值为 8.1 nM。它靠剂量依赖性抑制凝血酶受体激活肽 (TRAP) 诱导的血小板聚集。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 478 | 现货 | ||
5 mg | ¥ 987 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,950 | 现货 | ||
50 mg | ¥ 5,570 | 现货 | ||
100 mg | ¥ 7,570 | 现货 | ||
500 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,120 | 现货 |
产品描述 | Vorapaxar (MK-5348) (SCH 530348) is an effective and orally active thrombin receptor (PAR-1) antagonist (Ki: 8.1 nM). |
靶点活性 | PAR1:8.1 nM(Ki) |
体外活性 | SCH 530348 is a synthetic tricyclic 3-phenylpyridine and an orally active himbacine-based thrombin-receptor antagonist. SCH 530348 shows potent inhibition of thrombin-induced platelet aggregation with an IC50 of 47 nM and haTRAP-induced platelet aggregation with an IC50 of 25 nM, whereas it shows no inhibition of platelet aggregation induced by other agonists such as ADP, collagen and a PAR-4 agonist peptide. SCH 530348 also has no affect on the prothrombin time (PT), partial thromboplastin time (PTT), or activated partial thromboplastin time (aPTT). Moreover, SCH 530348 causes no increase in the bleeding time or in surgical bleeding compared with inactive control. SCH530348 is found to be selective for PAR-1 when tested over a number of ion channels and receptors, including PAR-4 receptor. [1] |
体内活性 | SCH 530348 is well absorbed in rat (68%; 10 mg/kg) and in monkey (82%; 1 mg/kg) models. Tmax is observed at about 3 h in rats and 1 h in monkeys. The elimination half-life is 5.1 h in rats and 13 h in monkeys. The oral bioavailability is 33% in rats and 86% in monkeys. In preclinical studies in cynomolgus monkey platelets, oral administration of SCH 530348 at a dose greater than 0.1 mg/kg resulted in 100% inhibition of thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation for 24 h with partial recovery occurring at 48 h. [1] |
别名 | SCH 530348, MK-5348, 沃拉帕沙 |
分子量 | 492.58 |
分子式 | C29H33FN2O4 |
CAS No. | 618385-01-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 92 mg/mL (186.8 mM)
DMSO: 92 mg/mL (186.8 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.0301 mL | 10.1506 mL | 20.3013 mL | 50.7532 mL |
5 mM | 0.406 mL | 2.0301 mL | 4.0603 mL | 10.1506 mL | |
10 mM | 0.203 mL | 1.0151 mL | 2.0301 mL | 5.0753 mL | |
20 mM | 0.1015 mL | 0.5075 mL | 1.0151 mL | 2.5377 mL | |
50 mM | 0.0406 mL | 0.203 mL | 0.406 mL | 1.0151 mL | |
100 mM | 0.0203 mL | 0.1015 mL | 0.203 mL | 0.5075 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vorapaxar 618385-01-6 GPCR/G Protein Protease-activated Receptor Protease Activated Receptor (PAR) Inhibitor MK 5348 SCH530348 MK5348 SCH-530348 SCH 530348 Thrombin receptors inhibit MK-5348 沃拉帕沙 inhibitor